p2g12
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01403792)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, passive
Human immunodeficiency virus immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- p2g12
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02923999 | Phase 1 | Mar 1, 2017 | University of London |
| NCT01403792 | Phase 1 | Jun 1, 2011 | European Commission, University of London |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of London | Academic/Hospital | 2 | 2 | 1 | 2011 |
| European Commission | Government | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1